Therapy of malignant neoplasias

Abstract

The present invention provides a method for the treatment of malignant neoplasias comprising the step of administering an L-phenylalanine conjugated to a beta- or alpha-emitting isotope to a subject in the need thereof. Moreover, the invention provides a method for the monitoring of the progress of such treatment of malignant neoplasias.

1 . A method for the treatment of prostatic or breast cancer, the method comprising the steps of administering a L-phenylalanine conjugated to an alpha-, beta- or Auger-electron emitting isotope selected from the group consisting of bromine-76, bromine-77, bromine-82, iodine-124, iodine-125, iodine-131 and astatine-211 to a subject in the need thereof. 
     
     
         2 - 3 . (canceled) 
     
     
         4 . The method according to  claim 1 , wherein the conjugated L-phenylalanine is administered intravenously. 
     
     
         5 . The method according to  claim 1 , wherein the irradiation dose of the alpha- beta- or Auger-electron emitting isotope conjugated to the L-phenylalanine is in the range of 0.1 to 1000 MBq/kg body weight. 
     
     
         6 . The method according to  claim 1 , wherein the irradiation dose of the alpha-, beta- or Auger-electron emitting isotope conjugated to the L-phenylalanine is administered as a single dose once or as a fractionated dose in 2 to 60 fraction doses. 
     
     
         7 . The method according to  claim 1 , wherein the conjugated L-phenylalanine is 4-[ 131 I]iodo-L-phenylalanine or 4-[ 211 At]astatine-L-phenylalanine or 4-[ 124 I]iodo-L-phenyalanine (IPA-124). 
     
     
         8 . The method according to  claim 1 , further comprising the step of a treatment of the subject by a concomitant therapy selected from the group consisting of a surgical therapy, a chemotherapy, a radiotherapy, an immunotherapy, a gene therapy, a vaccine therapy, an antisense nucleotide therapy, an intracavitary therapy, or a device-based treatment. 
     
     
         9 . The method according to  claim 8 , wherein the concomitant therapy is a radiotherapy wherein the irradiation is started in a period of 0 to 7 days subsequent to the administration of the conjugated L-phenylalanine. 
     
     
         10 . The method according to  claim 1 , wherein the subject is a human subject. 
     
     
         11 . A method for the monitoring of the progress of a treatment of prostatic or breast cancer the method comprising the steps:
 (a) administering a L-phenylalanine conjugated to an alpha-, beta- or Auger-electron emitting isotope selected from the group consisting of bromine-76, bromine-77, bromine-82, iodine-124, iodine-125, iodine-131 and astatine-211 to a subject in the need thereof, and   (b) localizing and/or dosimetrically measuring the conjugated L-phenylalanine in the subject by using a γ-camera.   
     
     
         12 . The method according to  claim 11 , wherein the conjugated L-phenylalanine is localized and/or dosimetrically measured at least 0 to 7 days, preferably 0.5 to 48 h subsequent to its administration.